Cargando…

Management of Advanced Heart Failure in Children with Cancer Therapy-Related Cardiac Dysfunction

The evolution of cancer therapies has led to marked improvement in survival of those affected by childhood malignancies, while also increasing the recognition of early and late toxicities associated with cancer therapies. Cardiotoxicity can include cardiomyopathy/heart failure, coronary artery disea...

Descripción completa

Detalles Bibliográficos
Autores principales: Tunuguntla, Hari P., Puri, Kriti, Denfield, Susan W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534565/
https://www.ncbi.nlm.nih.gov/pubmed/34682138
http://dx.doi.org/10.3390/children8100872
_version_ 1784587583463882752
author Tunuguntla, Hari P.
Puri, Kriti
Denfield, Susan W.
author_facet Tunuguntla, Hari P.
Puri, Kriti
Denfield, Susan W.
author_sort Tunuguntla, Hari P.
collection PubMed
description The evolution of cancer therapies has led to marked improvement in survival of those affected by childhood malignancies, while also increasing the recognition of early and late toxicities associated with cancer therapies. Cardiotoxicity can include cardiomyopathy/heart failure, coronary artery disease, stroke, pericardial disease, arrhythmias, and valvular and vascular dysfunction as a result of exposure to chemotherapy and/or radiation. Anthracyclines remain the most common cause of chemotherapy-induced cardiomyopathy (CCM) with varying clinical presentations including: acute, early onset, and late-onset. Many individuals develop cardiac dysfunction over the long-term, ranging from subclinical cardiac dysfunction to end-stage symptomatic heart failure. The focus of this review is on characterization of symptomatic heart failure in children with cancer therapy-related cardiac dysfunction (CTRCD) primarily due to CCM and utilization of advanced heart failure therapies, including ventricular assist device (VAD) support and heart transplantation, with consideration of unique patient-related factors.
format Online
Article
Text
id pubmed-8534565
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85345652021-10-23 Management of Advanced Heart Failure in Children with Cancer Therapy-Related Cardiac Dysfunction Tunuguntla, Hari P. Puri, Kriti Denfield, Susan W. Children (Basel) Review The evolution of cancer therapies has led to marked improvement in survival of those affected by childhood malignancies, while also increasing the recognition of early and late toxicities associated with cancer therapies. Cardiotoxicity can include cardiomyopathy/heart failure, coronary artery disease, stroke, pericardial disease, arrhythmias, and valvular and vascular dysfunction as a result of exposure to chemotherapy and/or radiation. Anthracyclines remain the most common cause of chemotherapy-induced cardiomyopathy (CCM) with varying clinical presentations including: acute, early onset, and late-onset. Many individuals develop cardiac dysfunction over the long-term, ranging from subclinical cardiac dysfunction to end-stage symptomatic heart failure. The focus of this review is on characterization of symptomatic heart failure in children with cancer therapy-related cardiac dysfunction (CTRCD) primarily due to CCM and utilization of advanced heart failure therapies, including ventricular assist device (VAD) support and heart transplantation, with consideration of unique patient-related factors. MDPI 2021-09-30 /pmc/articles/PMC8534565/ /pubmed/34682138 http://dx.doi.org/10.3390/children8100872 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Tunuguntla, Hari P.
Puri, Kriti
Denfield, Susan W.
Management of Advanced Heart Failure in Children with Cancer Therapy-Related Cardiac Dysfunction
title Management of Advanced Heart Failure in Children with Cancer Therapy-Related Cardiac Dysfunction
title_full Management of Advanced Heart Failure in Children with Cancer Therapy-Related Cardiac Dysfunction
title_fullStr Management of Advanced Heart Failure in Children with Cancer Therapy-Related Cardiac Dysfunction
title_full_unstemmed Management of Advanced Heart Failure in Children with Cancer Therapy-Related Cardiac Dysfunction
title_short Management of Advanced Heart Failure in Children with Cancer Therapy-Related Cardiac Dysfunction
title_sort management of advanced heart failure in children with cancer therapy-related cardiac dysfunction
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534565/
https://www.ncbi.nlm.nih.gov/pubmed/34682138
http://dx.doi.org/10.3390/children8100872
work_keys_str_mv AT tunuguntlaharip managementofadvancedheartfailureinchildrenwithcancertherapyrelatedcardiacdysfunction
AT purikriti managementofadvancedheartfailureinchildrenwithcancertherapyrelatedcardiacdysfunction
AT denfieldsusanw managementofadvancedheartfailureinchildrenwithcancertherapyrelatedcardiacdysfunction